Compare Regeneron Pharmaceuticals Inc (REGN) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Weibo Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Weibo Corp trades at $7.85 (market cap $1.97B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 35.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.63%). Which is the better fit depends on your goals.
| REGN | WB | |
|---|---|---|
Market Cap | $70.79B | $1.97B |
Sector | Health | Media |
52-Week High | $812.27 | $12.83 |
52-Week Low | $545.46 | $7.20 |
Enterprise Value | $64.74B | $1.24B |
Dividend Yield | 0.56% | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Weibo (WB) trades at $8.00, up 3.23% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.15% net income margin and trades at discounted valuations including a P/E of 5.59 and P/B of 0.51. Recent earnings missed expectations for three consecutive quarters, but the company maintains robust cash flow generation and a solid balance sheet with $2.35 billion in cash.
The outlook is mixed: deep value metrics and analyst buy ratings (45%) support upside potential, but competitive pressures and recent earnings misses pose risks. The stock's 8% dividend yield provides income support while investors await improved execution and AI monetization opportunities to drive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
